Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Int Immunopharmacol ; 120: 110300, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37192553

ABSTRACT

There has not been much researchs on the biological relationship between myeloid-derived suppressor cells (MDSCs) and mesenchymal stem cells (MSCs). The goal of the current work is to examine how these cells cooperate with one another in a rat model of adjuvant-induced arthritis (AIA). Three groups of equal numbers of rats were created; the first group served as the control. Complete Freund's adjuvant (CFA) was injected into the second group to induce AIA. The third group underwent MSCstreatment. Three weeks later, ANA, IL-1ß, IL-4, IL-6, IL-10, TNF-α, IFN-γ, M-CSF, iNOS and Arg-1 were determined using ELISA. Flowcytometric studies for MDSCs using CD11bc + and His48 + antibodies were performed. Current results showed significantly higher levels of WBCs, ANA, IL-1, IL-4, IL-6, IL-10, TNF-α, M-CSF, iNOS and Arg-1 along with a significant rise in MDSCs % in the AIA group compared to the control group. As opposed to AIA animals, MSCs administration resulted in a considerable improvement in cytokine levels, supporting the immunomodulation function of MSCs. Histological examination of the joints in the AIA group revealed articular cartilage degradation as well as infiltration of inflammatory cells and fibroplasia. These several evidences suggested that MDSCs may perform various roles in autoimmunity. Understanding how MDSCs and MSCs contribute to arthritis may help their prospective application in immunotherapy. Therefore, the reciprocal collaboration of MSCs and MDSCs must therefore be the subject of new investigations, which can offer new platforms for the development of more effective and individualized therapies for the treatment of immunological illnesses.


Subject(s)
Arthritis, Experimental , Mesenchymal Stem Cells , Myeloid-Derived Suppressor Cells , Rats , Animals , Interleukin-10 , Myeloid-Derived Suppressor Cells/pathology , Tumor Necrosis Factor-alpha , Interleukin-6 , Macrophage Colony-Stimulating Factor , Interleukin-4 , Mesenchymal Stem Cells/pathology
2.
Mater Sci Eng C Mater Biol Appl ; 65: 151-63, 2016 Aug 01.
Article in English | MEDLINE | ID: mdl-27157738

ABSTRACT

This paper upraises delivery and therapeutic actions of galantamine drug (GAL) against Alzheimer's disease (AD) in rat brain through attaching GAL to ceria-containing hydroxyapatite (GAL@Ce-HAp) as well ceria-containing carboxymethyl chitosan-coated hydroxyapatite (GAL@Ce-HAp/CMC) nanocomposites. Physicochemical features of such nanocomposites were analyzed by XRD, FT-IR, Raman spectroscopy, UV-vis spectrophotometer, N2-BET, DLS, zeta-potential measurements, SEM, and HR-TEM. Limited interactions were observed in GAL@Ce-HAp with prevailed existence of dispersed negatively charged rod-like particles conjugated with ceria nanodots. On contrary, GAL@Ce-HAp/CMC was well-structured developing aggregates of uncharged tetragonal-shaped particles laden with accession of ceria quantum dots. Such nanocomposites were i.p. injected into ovariectomized AD albino-rats at galantamine dose of 2.5mg/kg/day for one month, then brain tissues were collected for biochemical and histological tests. GAL@Ce-HAp adopted as a promising candidate for AD curativeness, whereas oxidative stress markers were successfully upregulated, degenerated neurons in hippocampal and cerebral tissues were wholly recovered and Aß-plaques were vanished. Also, optimizable in-vitro release for GAL and nanoceria were displayed from GAL@Ce-HAp, while delayed in-vitro release for those species were developed from GAL@Ce-HAp/CMC. This proof of concept work allow futuristic omnipotency of rod-like hydroxyapatite particles for selective delivery of GAL and nanoceria to AD affected brain areas.


Subject(s)
Alzheimer Disease/drug therapy , Cerium/chemistry , Durapatite/chemistry , Galantamine/administration & dosage , Nanocomposites/chemistry , Aluminum Chloride , Aluminum Compounds/toxicity , Alzheimer Disease/chemically induced , Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Animals , Brain/metabolism , Brain/pathology , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Chitosan/analogs & derivatives , Chitosan/chemistry , Chlorides/toxicity , Disease Models, Animal , Drug Carriers/chemistry , Dynamic Light Scattering , Female , Galantamine/chemistry , Hippocampus/metabolism , Hippocampus/pathology , Ovariectomy , Rats , Spectroscopy, Fourier Transform Infrared , X-Ray Diffraction
3.
Mater Sci Eng C Mater Biol Appl ; 48: 599-610, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25579963

ABSTRACT

The present study clarifies co-therapy action of deliveries from their textural changes point of view. Methotrexate (MTX) was immobilized onto biodegradable lignin, silica gel and iron/silica nanocomposite. Loaded-MTX was i.p. injected into albino rats at doses of 0.25 and 0.5mg/kg/week for 2.5months, after which spleen, liver, testes and knee joint tissues were collected for tests. IFN-γ and IL-17A mRNA gene expressions in spleen in all biological samples were determined by RT-PCR. Physicochemical features of drug carriers were monitored by XRD, BET-PSD, SEM and TEM. Drug inflammatory-site targeting was found to be closely related to the physico-features of deliverers. The interlayered lignin of micro- and meso-pore channels directed MTX toward concealed infected cells in liver and testes tissues, while meso-structured silica flacks satisfied by gathering MTX around knee joints. The magneto-silica nanocomposite targeted MTX toward spleen tissue, which is considered as a lively factory for the production of electron rich compounds.


Subject(s)
Antirheumatic Agents , Arthritis, Rheumatoid/drug therapy , Cellulose , Drug Carriers , Methotrexate , Saccharum/chemistry , Silica Gel , Animals , Antirheumatic Agents/chemistry , Antirheumatic Agents/pharmacokinetics , Antirheumatic Agents/pharmacology , Arthritis, Rheumatoid/metabolism , Arthritis, Rheumatoid/pathology , Cellulose/chemistry , Cellulose/pharmacokinetics , Cellulose/pharmacology , Disease Models, Animal , Drug Carriers/chemistry , Drug Carriers/pharmacokinetics , Drug Carriers/pharmacology , Knee Joint/metabolism , Knee Joint/pathology , Magnetic Fields , Male , Rats , Silica Gel/chemistry , Silica Gel/pharmacokinetics , Silica Gel/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...